Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 4
Submit an article Journal homepage
14
Views
1
CrossRef citations to date
0
Altmetric
Articles

Frequency of acquired von Willebrand’s disease in children with congenital heart disease

Mehmet Tayip ArslanDept. of Pediatrics, Ege University Medical Faculty, Izmir, Turkey.Correspondence[email protected]
,
Ruhi OzyurekDept. of Pediatric Cardiology, Ege University Medical Faculty, Izmir, Turkey.
,
Kaan KavakliDept. of Pediatric Hematology, Ege University Medical Faculty, Izmir, Turkey.
,
Erturk LeventDept. of Pediatric Cardiology, Ege University Medical Faculty, Izmir, Turkey.
,
Zulal UlgerDept. of Pediatric Cardiology, Ege University Medical Faculty, Izmir, Turkey.
,
Dolunay GursesDept. of Pediatric Cardiology, Ege University Medical Faculty, Izmir, Turkey.
,
Bedir AkyolDept. of Pediatric Cardiology, Ege University Medical Faculty, Izmir, Turkey.
&
Yuksel AtayDept. of Cardiovascular Surgery; Ege University Medical Faculty, Izmir, Turkey.
 show all
Pages 403-408 | Received 24 Apr 2006, Accepted 28 Mar 2007, Published online: 23 May 2017

References

  • Bahnson HT, Ziegler RF. A consideration of the causes of death following operation for congenital heart disease of the cyanotic type. Surg Gynecol Obstet 1950; 90: 60–76.
  • Hartmann RC. A hemorrhagic disorder occurring in patients with cyanotic congenital heart disease. Bull Johns Hopkins Hosp 1952; 91: 49–67.
  • Colon-Otero G, Gilchrist GS, Holcomb GR, Ilstrup DM, Bowie EJ. Preoperative evaluation of hemo stasis in patients with congenital heart disease. Mayo Clin Proc 1987; 62: 379–85.
  • Maurer HM, McCue CM, Robertson LW, Haggins JC. Cor-rection of platelet dysfunction and bleeding in cyanotic con-genital heart disease by simple red cell volume reduction. Am J Cardiol 1975; 35: 831–5.
  • Henriksson P, Varendh G, Lundstrom NR. Haemostatic defects in cyanotic congenital heart disease. Br Heart J1979; 41: 23-7.
  • Gross S, Keefer V, Liebman J. The platelets in cyanotic con-genital heart disease. Pediatrics 1968; 42: 651–8.
  • Waldman JD, Czapek EE, Paul MH, Schwartz AD, Levin DL, Schindler S. Shortened platelet survival in cyanotic heart disease. J Pediatr 1975; 87: 77–9.
  • Goldschmidt B. Effect of vitamin K on clotting factors in children with congenital cyanotic heart disease. Acta Paedi-atr Acad Sci Hung 1970; 11: 135–9.
  • Tran TC, Mannucci PM, Schneider P, Federici AB, Bach-mann F. Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lym-phoma. Br J Haematol 1985; 61: 307–14.
  • Duran-Saurez JR, Pico M, Zuazu J, Cortes M, Monasterio J, Tringiner J. Acquired von Willebrand's disease caused by a chronic granulocytic leukemia. Br J Haematol 1981; 48: 173–5.
  • Mannucci PM, Mari D. Antibodies to factor VIII/von Wille-brand factor in congenital and acquired von Willebrand’s disease. Prog Clin Biol Res 1984; 150: 109–22.
  • Kreuz W, Linde R, Funk M, Meyer-Schrod R, Foll E, Nowak-Gottl U, Jacobi G, Vigh Z, Scharrer I. Induction of von Willebrand disease type 1 by valproic acid. Lancet 1990; 335: 1350–1.
  • Conrad ME, Latour LE Acquired von Willebrand’s disease, IgE polyclonal gammopathy and griseofulvin therapy. Am J Hemat 1992; 41: 143.
  • Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: evidence for height-ened proteolysis of von Willebrand factor. Am J Hematol 1995; 49: 83–6.
  • Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Wille-brand factor. Proc Natl Acad Sci USA 1990; 87: 6306–10.
  • Pareti Fl, Lattuada A, Bressi C, Zanobini M, Sala A, Stef-fan A, Ruggeri ZM. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290–5.
  • Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758–61.
  • Froom P, Margulis T, Grenadier E, Palant A, David M, Aghai E. Von Willebrand factor and mitral valve prolapse. Thromb Haemost 1988; 60: 230–1.
  • Rauch R, Budde U, Koch A, Girisch M, Hofbeck M. Acquired von Willebrand syndrome in children with patent ductus arteriosus. Heart 2002; 88: 87–8.
  • McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Fac-tor VIII levels and blood group antigens. Thromb Haemost 1983; 50: 757.
  • Vincentelli A, Susen S, Le Tourneau TL, Six I, Fabre 0, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic steno-sis. N Engl J Med 2003; 349: 343–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.